Skip to main content
. 2022 Apr 6;8(3):184–190. doi: 10.1002/cdt3.24

Figure 1.

Figure 1

Complement pathways and certain targets of complement inhibitors. The names of the products of monoclonal antibodies are shown in blue, while the names of peptides or small molecules are shown in red, recombinant protein in yellow, and gene therapies in green. Blue lines indicate certain targets of the complement system. From left to right: ABP959, tesidolumab, REGN3918, mubodina, coversin, RA101495, cemdisiran, and zimura inhibit C5; narsoplimab inhibits mannose‐binding protein‐associated serine protease 2 (MASP‐2) of the lectin pathway; MicroCept, TP10/CDX‐1135 inhibits C3 and C5 convertases; IFX‐1 inhibits C5a; avacopan, IPH5401 inhibits C5a receptor; pegcetacoplan (formerly APL‐2), AMY‐101, and mini‐FH/AMY‐201 inhibit C3 and C3 convertase activity; lampalizumab and danicopan inhibit factor D; CLG561 inhibits properdin; iptacopan and IONIS‐FB‐LRx inhibit factor B.